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Diagnostic and Therapeutic Challenges in
Patients With Coexistent Chronic Obstructive
Pulmonary Disease and Chronic Heart Failure
Thierry H. Le Jemtel, MD,* Margherita Padeletti, MD,† Sanja Jelic, MD†
New Orleans, Louisiana; and New York, New York
Chronic obstructive pulmonary disease (COPD) and heart failure (CHF) are common conditions. The prevalence
of COPD ranges from 20% to 30% in patients with CHF. The diagnosis of CHF can remain unsuspected in pa-
tients with COPD, because shortness of breath is attributed to COPD. Measurement of plasma B-type natriuretic
peptide (BNP) levels helps to uncover unsuspected CHF in patients with COPD and clinical deterioration. Nonin-
vasive assessment of cardiac function may be preferable to BNP to uncover unsuspected left ventricular (LV)
systolic dysfunction in patients with stable COPD. Patients with COPD or CHF develop skeletal muscle alterations
that are strikingly similar. Functional intolerance correlates with severity of skeletal muscle alterations but not
with severity of pulmonary or cardiac impairment in COPD and CHF, respectively. Improvement of pulmonary or
cardiac function does not translate into relief of functional intolerance in patients with COPD or CHF unless skel-
etal muscle alterations concomitantly regress. The mechanisms responsible for skeletal muscle alterations are
incompletely understood in COPD and in CHF. Disuse and low-level systemic inflammation leading to protein
synthesis/degradation imbalance are likely to contribute. The presence of COPD impacts on the treatment of
CHF, as COPD is still viewed as a contraindication to beta-blockade. Therefore, COPD often deprives patients
with CHF due to LV systolic dysfunction of the most beneficial pharmacologic intervention. A large body of
data indicates that patients with COPD tolerate well selective beta-blockade that should not be denied to
CHF patients with concomitant COPD. (J Am Coll Cardiol 2007;49:171–80) © 2007 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.046i
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chronic heart failure (CHF) and chronic obstructive pul-
onary disease (COPD) are 2 commonly encountered
onditions in clinical practice: 14 million Americans have
OPD and 5 million have CHF (1,2). Notwithstanding the
se of tobacco as a common risk factor, the sheer number of
atients with COPD and CHF accounts for their frequent
oexistence. Among the comorbid conditions commonly
ssociated with CHF, COPD is the one that most delays
he diagnosis of CHF and is most often advocated for
onadherence to therapeutic guidelines, especially beta-
lockade (BB) (3). The present review aims to address the
iagnostic and therapeutic problems raised by the coexist-
nce of COPD and CHF. The first aim of the review is to
utline why COPD delays the diagnosis of CHF and how
o avoid any diagnostic delay. The second aim is to
mphasize the important role of skeletal muscle alterations
n limiting functional capacity in patients with COPD and
n patients with CHF and to advocate new therapeutic
rom the *Division of Cardiology, Tulane University, New Orleans, Louisiana; and
he †Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia
niversity College of Physicians and Surgeons, New York, New York.a
Manuscript received June 19, 2006; revised manuscript received August 14, 2006,
ccepted August 14, 2006.nterventions to manage skeletal muscle alterations in
hronic conditions. The third aim is to summarize the data
hat demonstrate the safety and efficacy of BB in patients
ith COPD and to promote a greater use of BB in patients
ith coexistent COPD and CHF.
mpact of COPD on the Diagnosis of CHF
verlooked CHF in patients with COPD. Patients with-
ut known respiratory disease who complain of dyspnea or
atigue during exercise undergo noninvasive cardiac imaging
hat establishes the diagnosis of heart failure when it
emonstrates left ventricular (LV) dysfunction. When pa-
ients with stable COPD complain of dyspnea or fatigue
uring exercise, these symptoms are often attributed to
OPD, noninvasive cardiac imaging is not performed, and
V dysfunction remains undetected (4). In all studies but 1,
he prevalence of COPD ranges from 20% to 32% in
atients with CHF (4–11). The outlier study reported a
0% prevalence of COPD in patients hospitalized for CHF
10). The risk ratio of developing CHF is 4.5 (95%
onfidence interval [CI] 4.25 to 4.95) in COPD patients
ompared with age-matched controls without COPD after
djustments for cardiovascular risk factors (12). The rate-
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Diagnosis and Therapy of Coexistent COPD and CHF January 16, 2007:171–80adjusted hospital prevalence of
CHF is 3 times greater among
patients discharged with a diag-
nosis of COPD compared with
patients discharged without
mention of COPD (13). Fur-
thermore, the prevalence of hos-
pitalization for CHF increased at
a much higher rate from 1971 to
2001 when discharge coding in-
cluded COPD as primary or sec-
ondary diagnosis than when
COPD was not mentioned as a
diagnosis (13). The Northern
California Kaiser Permanente
Medical Program has reported
an age-adjusted relative rate of
hospitalization for CHF of 5.55
95% CI 4.71 to 5.73) and an odds ratio of CHF as a
omorbidity of 8.48 (95% CI 7.65 to 9.40) in COPD
atients compared with controls (14).
OPD as a cardiovascular risk. The high prevalence of
HF in patients with COPD is not surprising, because
OPD patients are at increased risk of cardiovascular
ortality or morbidity independently of other risk factors,
ncluding tobacco use. Forced expiratory volume in 1 s
FEV1) is as good a predictor of cardiovascular mortality as
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
BB  beta-blockade
BNP  B-type natriuretic
peptide
CHF  chronic heart failure
CI  confidence interval
COPD  chronic
obstructive pulmonary
disease
FEV1  forced expiratory
volume in 1 s
LV  left ventricular
SM  skeletal muscle
Figure 1 Evaluation of Heart Failure During COPD Exacerbation
Brain natriuretic peptide (BNP) serum levels and detection of chronic heart failure
CHF is unlikely when BNP levels are 100 pg/ml. A BNP level of 500 pg/ml ind
to 500 pg/ml indicate right-sided (R) heart failure, moderate left-sided heart failure
cardiac imaging needs to be performed and therapy adjusted. 2D  2-dimensionaerum cholesterol (15). Ischemic heart disease, and not
espiratory failure, is the leading cause of death in COPD
atients, with only a small fraction dying of respiratory
ailure (16). The relationship between COPD and cardio-
ascular events remains unclear. Patients with COPD are
ot at increased risk for hypertension or LV hypertrophy;
owever, they consistently show evidence of low-grade
ystemic inflammation that plays an increasingly recognized
ole in the pathogenesis of atherosclerosis (17). Patients
ith severe COPD are 2.18 and 2.74 times more likely to
ave elevated and highly elevated, respectively, circulating
-reactive protein levels than control subjects (18). A
orking hypothesis to account for the high prevalence of LV
ystolic dysfunction in patients with COPD is that low-grade
ystemic inflammation accelerates progression of coronary
therosclerosis, which ultimately results in ischemic cardiomy-
pathy. Such a hypothesis fits the clinical observation of a high
ncidence of LV wall motion abnormalities noted in patients
ith COPD and LV dysfunction (19).
ncovering CHF during COPD exacerbation. The di-
gnostic usefulness of measuring B-type natriuretic peptide
BNP) plasma levels in patients presenting to an emergency
oom with dyspnea is now well established and was recently
eviewed (20–22) (Fig. 1). A BNP level of 500 pg/ml in
patient with known COPD consulting for clinical deteri-
ration alerts to the presence of overt CHF whether or not
he patient is known to have CHF. A BNP level of 500
in patients with exacerbation of chronic obstructive pulmonary disease (COPD).
overt left-sided (L) CHF and the need for treatment. BNP levels ranging from 100
oth and the need for treatment. Once patients have returned to baseline status,
 angiotensin-converting enzyme; RNV  radionuclide ventriculography.(CHF)
icates
, or b
l; ACE
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January 16, 2007:171–80 Diagnosis and Therapy of Coexistent COPD and CHFg/ml does not differentiate cardiac from pulmonary dete-
ioration as the cause of clinical worsening but indicates that
HF therapy should be initiated or upgraded in addition to
reatment of COPD. In contrast, a BNP level of 100
g/ml argues against CHF decompensation as the cause of
linical deterioration but does not completely eliminate
cute heart failure as the triggering factor of clinical dete-
ioration (A. Maisel, personal communication, July 2006).
BNP level between 100 to 500 pg/ml points toward right
entricular failure, moderate LV failure, or both and the
eed to initiate therapy with angiotensin-converting en-
yme (ACE) inhibitors and possibly loop diuretics. Once
atients with COPD exacerbation have returned to their
aseline status, cardiac imaging needs to be performed and
herapy adjusted according to the findings.
scertaining CHF in patients with stable COPD. Be-
ause 20% to 25% of ambulatory patients with CHF have
NP levels of 100 pg/ml, echocardiography appears more
eliable than BNP levels to detect unsuspected LV systolic
ysfunction in patients with stable COPD (23) (Fig. 2).
adionuclide ventriculography (RNV) may be obtained
hen a poor acoustic window impedes evaluation of LV
unction by echocardiography in COPD patients.
Patients with COPD found to have an LV ejection fraction
f 40% need to receive full CHF therapy, including beta-
drenergic blockade. Patients with COPD with normal LV
jection fraction and normal LV mass or LV filling do not
Figure 2 Evaluation of Heart Failure in Stable COPD Patients
Two-dimensional (2D) Doppler echocardiography is indicated in patients with stabl
excludes chronic heart failure (CHF). No further therapy () is needed. When left v
is recommended. When LVEF is 40%, LV mass is increased, and left atrium is e
with angiotensin-converting enzyme (ACE) inhibitors and diuretics considered. Whe
(RNV) is indicated and therapy needs to be adjusted to the findings. Imp.  impaiequire CHF therapy. The diagnosis of diastolic heart failure is oarticularly difficult to establish in patients with COPD. The
iagnosis of diastolic heart failure needs to be entertained in
OPD patients with LV ejection fraction 40% and abnor-
al LV mass or enlarged left atrium by echocardiography or
mpaired LV filling by RNV, and the response to ACE
nhibitors and loop diuretics needs to be closely monitored.
tandard echocardiographic indices of LV diastolic dysfunc-
ion do not reliably permit the diagnosis of diastolic heart
ailure, but the diagnosis can be established by comprehensive
oppler echocardiography and myocardial tissue imaging,
hich provide evidence for impaired myocardial relaxation,
ecreased LV compliance, and increased LV filling pressure
24,25).
In summary, COPD is an important risk factor for cardio-
ascular morbidity and mortality in the general population.
hronic heart failure is often unrecognized despite its high
revalence in COPD patients. Elevated BNP plasma levels
hould alert to the presence of CHF in patients with COPD
xacerbation. The 20% to 30% prevalence of CHF in ambu-
atory patients with stable COPD mandates noninvasive as-
essment of LV function to avoid undue delays in the diagnosis
nd therapy of previously unrecognized CHF.
keletal Muscle Alterations
n Patients With CHF and COPD
lthough CHF and COPD primarily involve different
nic obstructive pulmonary disease (COPD). A normal (Nl) echocardiogram (echo)
lar (LV) ejection fraction (EF) is 40%, full CHF therapy, including beta-blockade,
d, the diagnosis of diastolic heart failure needs to be entertained and therapy
chocardiogram is technically (Tech.) inadequate, radionuclide ventriculographye chro
entricu
nlarge
n the e
red.rgans, patients with CHF and COPD develop strikingly
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Diagnosis and Therapy of Coexistent COPD and CHF January 16, 2007:171–80imilar skeletal muscle (SM) alterations (26,27). In brief,
M alterations in CHF and COPD include decreased
uscle strength and mass with reduced cross-sectional area,
ber shift with atrophy of type I oxidative fibers, and relative
ncrease in glycolytic type IIa and IIb fibers accompanied by
n increase in glycolytic and a decrease in oxidative enzy-
atic activities (27–29). Whether the enzymatic alterations
re the cause or consequence of the fiber shift remains to be
etermined. Use of 31-P nuclear magnetic resonance spec-
roscopy has demonstrated reduced concentration of high-
nergy phosphate at rest, which becomes more pronounced
uring exercise with a faster drop in pH and a slower
ephosphorylation after exercise in patients with CHF or
OPD compared with age-matched controls (27). Loss of
M mass and the resulting muscle atrophy have major
linical and therapeutic implications in CHF and COPD.
M atrophy in CHF and COPD. Muscle atrophy con-
ributes to muscle fatigue during exercise, which leads
atients with CHF or COPD to discontinue exercising
lthough they have not exhausted their cardiac or pulmo-
ary reserve (30,31). Peak oxygen uptake is linearly related
o SM mass in patients with CHF and or COPD (32–34).
s the disease progresses, SM atrophy worsens and patients
ith CHF or COPD become increasingly symptomatic
Fig. 3). Therapeutic interventions that improve LV and
ulmonary function in patients with CHF and COPD,
espectively, do not reliably reverse SM atrophy and thus do
ot consistently alleviate functional intolerance (35,36).
herefore, interventions that primarily aim at reversing SM
trophy are needed to complement existing interventions
hat improve cardiac and pulmonary function in patients
Figure 3 Progression of CHF and COPD
Time course of loss of cardiac or pulmonary function (A), loss of skeletal muscle m
(CHF) or chronic obstructive pulmonary disease (COPD). Curves A and C in CHF pa
Curve B in CHF patients and curves A, B, and C in COPD patients are based on cith CHF and COPD, respectively.echanisms of SM atrophy in CHF or COPD. The
vents and mechanisms that lead to SM atrophy are
ncompletely understood in patients with CHF and COPD.
uscle disuse, low-level systemic inflammation, and in-
reased oxidative stress contribute to reduced protein syn-
hesis and accelerated protein degradation and thus to SM
trophy (37) (Fig 4). Muscle disuse evolves as dyspnea and
atigue prompt patients to progressively avoid all physical
ctivities. Patients are often unaware of the progressive
ecline in physical activities, which is not readily quantifi-
B), and functional incapacity (C) during the progression of chronic heart failure
are based on data collected during studies of left ventricular dysfunction (101).
experience in the absence of quantitative data.
Figure 4 Mechanisms of Skeletal Muscle
Atrophy in Patients With CHF or COPD
Disuse, low-level systemic inflammation (Inflam.), and increased oxidative
(oxidat.) stress decrease protein synthesis while increasing protein degrada-
tion. CHF  chronic heart failure; COPD  chronic obstructive pulmonary
disease.ass (
tients
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January 16, 2007:171–80 Diagnosis and Therapy of Coexistent COPD and CHFble. However, the overt benefits of a rigorous training
rogram corroborate the importance of disuse as a cause of
M atrophy in patients with CHF or COPD (38,39).
esides SM disuse, low-level systemic inflammation and
ncreased oxidative stress are responsible for SM atrophy in
HF and COPD. Circulating levels of proinflammatory
ytokines are elevated in patients with CHF and COPD,
nd 8-isoprostanes are elevated in the pericardial fluid of
atients with CHF (40,41). The source of systemic inflam-
ation appears to be in the small airways in COPD and is
nclear in CHF (42,43).
ignaling pathways of disuse and inflammation. Both
isuse and inflammations set off SM atrophy by reducing
rotein synthesis, increasing protein degradation, or both
44) (Fig. 4). Reduced protein synthesis and increased
rotein degradation share common pathways (37). Insulin
esistance and reduced tissue concentration of insulin
rowth factor (IGF)-1 reduce phosphorylation of the
hosphatidyinositol-3-OH kinase, which in turn lowers
ctivation of Akt (protein kinase B), thereby decreasing
rotein synthesis via dephosphorylation of mTOR, a mam-
alian target of rapamycin and glucogen synthase kinase
45–49) (Fig. 5). Reduced Akt activation increases activity
f forkhead box O (FOXO) transcription factors, which in
urn activates the ubiquitin-proteasome pathway, resulting
n protein degradation (48–52) (Fig. 5). In addition, insulin
esistance and reduced tissue IGF-1 concentration activate
aspase-3 (53). After cleavage by activated caspase-3, myo-
brillar proteins are degraded by the ubiquitin-proteasome
athway (54). Whether apoptosis plays a significant role in
M atrophy remains controversial (55,56). The important
ole that the growth hormone (GH)/IGF-1 axis plays in
Figure 5 Signaling Pathways of Disuse and Inflammation
Reduced insulin growth factor-1 (IGF-1) tissue level and insulin resistance combine
reduces activation of Akt (protein kinase B), thereby reducing protein synthesis via
thase kinase (GSK). Reduced Akt activation increases activity of forkhead box O (F
promoting protein degradation. Reduced IGF-1 levels and insulin resistance activat
caspase-3 results in muscle apoptosis is controversial.ediating SM growth provides the rationale for the use of phrelin in patients with CHF or COPD (57). Ghrelin, a
ovel GH-releasing peptide acts through a mechanism that
s more potent and independent of hypothalamic GH-
eleasing hormone (58). Administration of ghrelin for
weeks improves functional capacity and alleviates SM
trophy in patients with CHF and in patients with COPD
59,60).
In summary, disuse, low-level systemic inflammation,
nd increased oxidative stress contribute to SM atrophy by
nhancing protein degradation and hindering protein syn-
hesis. Reduced IGF-1 muscle concentration provides the
ationale for modulation of the GH/IGF-1 axis. Prelimi-
ary results with ghrelin, a novel modulator of the GH/
GF-1 axis, are encouraging.
merging therapeutic approaches in CHF and COPD.
ince it was shown to lower mortality 2 decades ago, ACE
nhibition has been the cornerstone of treatment of CHF
61). More recently, ACE inhibition was shown to prevent
achexia and SM atrophy and to improve respiratory muscle
trength in patients with CHF (62–64). Because the ben-
ficial effects of ACE inhibition on muscles are partially
ediated by a reduction in angiotensin II levels, which in
urn attenuates the decline in IGF-1 levels, achieving
omplete ACE inhibition may be of special interest to
revent SM atrophy in CHF and potentially in COPD (65).
odulation of the renin-angiotensin system with ACE
nhibition or angiotensin receptor blockade (ARB) may
ave dual benefits in patients with COPD by lowering
ardiovascular risk and preventing lung injury (66,67).
owever, ARB failed to improve respiratory or SM
trength in patients with COPD without cardiovascular
iseases nor the exercise capacity or dyspnea score in
crease phosphorylation of phospatidyinositol-2-OH kinase (PI3K), which in turn
ed phosphorylation of mammalian target of rapamycin (mTOR) and glucogen syn-
transcription factors, thereby activating the ubiquitin-proteasome pathway and
ase-3, resulting in protein breakdown and degradation. Whether activatedto de
reduc
OXO)
e caspatients with COPD and pulmonary hypertension (68,69).
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Diagnosis and Therapy of Coexistent COPD and CHF January 16, 2007:171–80hen they receive ACE inhibitors, patients with COPD
re not at increased risk of cough or bronchospasm (70).
ccurrence of cough in patients with COPD is more likely
o be related to unsuspected CHF than to ACE inhibition.
Human menopausal gonadotropin-CoA reductase inhi-
ition with simvastatin inhibits development of emphy-
ema, inflammation, and pulmonary hypertension in a rat
odel of smoking-induced lung injury (71). Simvastatin
lso reverses pulmonary hypertension in a rat model of toxic
njury to the pulmonary vasculature (72). The pleiotropic
ffects and, especially, the anti-inflammatory action of
imvastatin are likely to mediate its benefits in experimental
odels. Administration of simvastatin for 14 weeks im-
roves LV ejection fraction and functional status in patients
ith CHF due to idiopathic cardiomyopathy (73). These
reliminary findings with simvastatin contrast with the
egative experience with tumor necrosis factor  antibodies
74,75). A nested case-control study of elderly COPD
atients with and without known CAD who were receiving
tatins, ACE inhibitors, or ARBs alone or a combination of
tatins with either ACE inhibitors or ARBs advocates that
hese agents may have cardiopulmonary protective proper-
ies (76). Statins alone and in combination with either ACE
nhibitors or ARBs reduced hospitalizations for COPD
76). Because only a minority of patients with CHF (4%)
ere included in that case-control COPD study, one cannot
xtrapolate the results to patients with coexistent CHF and
OPD. Whether these agents have dual cardiac and pul-
onary protective properties needs to be confirmed in
andomized clinical trials.
B in Patients With CHF and COPD
ong-term BB is underused in CHF patients (3,77). Un-
eruse of BB in CHF is largely due to the entrenched belief
hat it may precipitate respiratory deterioration when
OPD coexists with CHF. Few reports of acute broncho-
pasm after initiation of BB lead to exclusion of patients
ith coexistent CHF and COPD from large BB trials (78).
eta-blockers remain underprescribed to patients with
HF and COPD despite extensive safety data in patients
ith moderate to severe COPD (77,79,80).
elective beta-1 adrenergic blockade. Respiratory symp-
oms and FEV1 are not significantly worsened by selective
eta-1 blockade (B1B) in COPD patients (80–86). Selec-
ive B1B with metoprolol succinate or tartrate was well
olerated for 3 months by 50 patients with coexistent
schemic cardiac disease and mild to severe COPD (87).
atients remained free of adverse respiratory effects, and
EV1 was unchanged. Selective B1B does not attenuate
eta-2 receptor (B2R) agonist-induced bronchodilatation
82). The cumulative evidence from trials and meta-analysis
ndicates that selective B1B should not be withheld when
OPD coexists with cardiovascular diseases, because the
enefits of selective B1B in cardiac patients with COPD far
utweigh the risks (80,88). tonselective BB combined with alpha-blockade. The
afety profile of carvedilol and labetalol that combine
lpha-adrenergic blockade with nonselective BB is not as
ell-established as that of selective B1B in COPD. Labe-
alol at maximal dose does not affect FEV1 in COPD (79).
mong 89 patients with coexistent COPD and CHF who
eceived carvedilol for at least 3 months, only 13 did not
olerate carvedilol (89). The reasons for intolerance and the
resence of reversible airway obstruction were not specified.
hirty-one patients with coexistent CHF and COPD
ithout reversible airflow obstruction receiving a mean dose
f 29  19 mg daily carvedilol were followed for a mean
uration of 2.4 years (90). Only 1 patient did not tolerate
arvedilol because of COPD exacerbation. Cardiac size and
unction improved similarly in patients with coexistent
HF and COPD and in patients with CHF alone after
eceiving nonselective beta- and alpha-adrenergic blockade
or 24 months (89,91). Data regarding the use of carvedilol in
OPD patients with reversible airflow obstruction are not
vailable. In contrast to selective B1B, nonselective blockade
ttenuates B2R agonist-induced bronchodilatation.
linical experience with selective B1B and combined
onselective and alpha-blockade in COPD. Beta-
lockade with selective and nonselective agents does not
ffect the rate of hospitalization for COPD exacerbation in
atients with recent myocardial infarction, whereas it ben-
ficially impacts mortality (92,93). Although case studies
ave documented nonselective BB-triggered bronchospasm,
B with selective and nonselective agents does not appear to
ffect the rate of hospitalization for COPD exacerbation
94). Therefore, current guidelines from the Heart Failure
ociety of America recommend BB in all patients with
oexistent COPD and CHF (88). The use of BB in patients
ith COPD and CHF can be substantially and safely
ncreased by a structured outpatient program (95). The
linical experience and pulmonary effects of the 3 beta-
lockers currently approved for the treatment of CHF are
ummarized in Table 1.
Lastly, 3 issues regarding BB in COPD patients will be
riefly reviewed. They are time dependence of pulmonary
ffects, receptor selectivity, and concomitant use of BB and
eta-2 agonists.
ime dependence of BB-induced pulmonary effects. As
bserved with LV function, acute and long-term BB ap-
ears to have opposite effects on lungs. Airway hyper-
esponsiveness (AHR), as defined by an FEV1 decline of
20% after inhalation of metacholine, is associated with
ncreased mortality in patients with COPD (96). Acutely
dministered selective or nonselective BB increases AHR in
atients with COPD (82). However, after an initial in-
rease, long-term administration of carvedilol or nadolol
educes AHR in a murine model of asthma (97). No data
re presently available regarding the effects of long-term BB
n AHR in patients. Similarly, beta-receptor (BR) density,
lthough unaffected by acute BB, increases during long-
erm BB (97). Increased BR density may be beneficial as
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lase activity in airway smooth muscle and reduces
HR (98).
In summary, the detrimental effects of acute BB on AHR
ay with time convert into beneficial effects. Accordingly,
arly mild deterioration in pulmonary symptoms or FEV1 in
atients with coexistent CHF and COPD should not
rompt BB discontinuation. Close observation is recom-
ended and BB discontinuation is warranted when pulmo-
ary symptoms persist or worsen.
eceptor selectivity of BB. Selective B1Bs have a 20-fold
igher affinity for B1R than for B2R. Selective B1Bs are
resumably less likely to induce bronchoconstriction than
onselective BBs (99). However, the receptor selectivity of
Bs varies in experimental models (100). Receptor selectiv-
ty varies for the following reasons: 1) B2Rs predominate in
ronchial smooth muscle, whereas B1Rs account for 10%
nd 30% of beta-receptors in submucosal glands and alve-
lar walls, respectively (101); 2) selective B1Bs appear to
ose selectivity at the high end of dose ranging; 3) several
olymorphisms of beta-receptor have been reported; and 4)
xposure to agonists may alter B2Rs such that the affinity
or ligands is reduced 10-fold (102). Consequently, prior
xposure to beta agonists may reduce binding of antagonists
o B2Rs. It may explain the high tolerance for BB in COPD
atients who routinely inhale B2R agonists.
In summary, BB receptor selectivity varies in experimen-
al settings. Whether such variability has therapeutic impli-
ations remains unclear in patients with COPD.
oncomitant use of BB and inhaled beta-agonists. Owing
o the cardiovascular risks associated with the use of inhaled
2R agonists, nonselective BB may be particularly beneficial
n patients with CHF and COPD. Deleterious cardiovas-
ular effects of inhaled B2R agonists, the mainstay of
OPD therapy, are now increasingly recognized. Recent
eta-analysis of 5 single-dose and 6 longer-duration trials
f B2R agonists has underlined their adverse cardiovascular
ffects in COPD patients (103). Therapy with inhaled B2R
gonists is associated with an increased risk for CHF
ecompensation (adjusted OR 3.42, 95% CI 1.99 to 5.86)
nd all-cause mortality in patients with CHF (104,105).
nhaled B2R agonists induced adverse cardiac effects in
OPD patients with pre-existing cardiovascular disease
106). The adverse effects of B2R agonists are likely to be
xacerbated in COPD patients with coexistent CHF. The
fficacy of concomitant BB to offset the adverse cardiovas-
ular effects of B2R agonists in COPD patients with
oexistent CHF has not yet been assessed in clinical trials.
In summary, BB therapy should be attempted with selective
eta-1 adrenergic blockade or combined nonselective beta- and
lpha-adrenergic blockade in all CHF patients with concom-
tant stable COPD who do not have reversible airway obstruc-
ion. Selective BB is recommended in patients with CHF and
OPD who have reversible airway obstruction in the absence
f safety data regarding combined nonselective beta- andalpha-adrenergic blockade. Both selective beta-1 and com-T B M C FE
V 1
b
b
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R
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e avoided during COPD exacerbation until safety data are
vailable.
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